Balancing Access and Innovation in India's Shifting IP Regime, Remarks
8 Pages Posted: 14 Aug 2014 Last revised: 1 May 2015
Date Written: 2014
This Article is based on a lecture that was delivered at the Whittier Law Review’s Annual Symposium on November 8, 2013, titled “The Global Medicine Challenge: The Fine Line Between Incentivizing Innovation and Protecting Human Rights.” It compares the pharmaceutical patent regimes of the United States and India, and discusses some of the inefficiencies of both systems. The Article analyzes the controversial Indian case of Novartis’ blockbuster drug Gleevec, and suggests that this case is an opportunity for both countries to consider changes to their patent laws. Smarter, rather than more, intellectual property protection could improve public health.
Suggested Citation: Suggested Citation